Contact

Dr. Torsten Knieß

Department Head
Production of Radio­pharma­ceuticals
t.kniessAthzdr.de
Phone: +49 351 260 2760

HZDR is holding marketing authorizations for following PET radiopharmaceuticals

  • [18F]FDG ([18F]fluoro-2-desoxy-D-glucose) - GlucoRos© since 2005
    [approval No. 63584.00.00]
  • [18F]Sodium fluoride for injection - NaFRos© since 2012
    [approval No. 79232.00.00]
  • [18F]FDOPA (3,4-dihydroxy-6-18F-fluoro-L-phenylalanine) – DOPARos© since 2017
    [approval No 87703.00.00]

Disposal and shipment of GlucoRos©, NaFRos© and DOPARos© is performed by our partner ROTOP Pharmaka GmbH.

The following PET radiopharmaceuticals were produced in frame of our manufacturing license for in house application

  • [11C]Methionin (for investigation of brain tumors and amino acid transporters)
  • [18F]FMISO ([18F]Fluoromisonidazole for evaluation of tumor hypoxia)

Additionally, HZDR is approved by GE Healthcare as manufacturing facility of

  • [18F]Flutemetamol (Vizamyl©), a new radiotracer used for estimation of ß-amyloid neuritic plaque density in human brain.

Further PET radiopharmaceuticals can be provided for pre-clinical research on request

  • [18F]FLT ([18F]fluorothymidine) and
  • [18F]FET ([18F]fluoroethyltyrosine).

Contact

Dr. Torsten Knieß

Department Head
Production of Radio­pharma­ceuticals
t.kniessAthzdr.de
Phone: +49 351 260 2760